<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00471705</url>
  </required_header>
  <id_info>
    <org_study_id>PECET-001</org_study_id>
    <nct_id>NCT00471705</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.</brief_title>
  <official_title>Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Antioquia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad de Antioquia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cutaneous leishmaniasis (CL) is a worldwide disease, endemic in 88 countries, that has shown
      an increasing incidence the last two decades. It is estimated that in 2005, about of 20,000
      new cases of CL were diagnosed in Colombia.

      So far, pentavalent antimony compounds have been considered the treatment of choice with a
      percentage of cure of about 85%. However, the high efficacy of these drugs is counteracted by
      their adverse events and disadvantages. Previous studies have shown that miltefosine could be
      a potential alternative of treatment for CL.

      The main objective of this study is to evaluate the efficacy and safety of miltefosine or
      thermotherapy for the treatment for CL. In this study the efficacy of oral treatment of
      miltefosine 150 mg/day for 28 days or a thermotherapy device used for one session at 50
      celsius degrees during 30 seconds will be compared with the standard treatment of
      intramuscular injections of 20 mg/Kg/day of pentavalent antimonials (GlucantimeÒ) for 20 days
      in CL parasitologically proven patients.

      This trial will be conducted according to the International approved GCP (Good Clinical
      Practice) guidelines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of Efficacy and Safety of Miltefosine for Cutaneous Leishmaniasis in Colombia
      Leishmaniasis is taking dramatic dimensions in Colombia, due to its rapid expansion,
      reemergence (which has made Colombia became in the second South American country in levels of
      annual incidence) the appearance of new infection sources, the entrance of the vector to the
      homes, the urbanization of the disease, the higher population in risk of infection, the
      absence of adequate medications ( safe, non-expensive, easily available, with oral or topic
      route of administration) and the higher resistance to the only available medication for its
      treatment. It is estimated that in 2005 more than 20,000 new cases were diagnosed; 10,265 of
      them among the Colombian military forces personnel, but it is well known that in most of the
      rural areas the major proportion of cases are not diagnosed and the people cannot reach to an
      adequate treatment and they have to use empiric options.

      On the other hand, the Program for Research and Control in tropical diseases (PECET) is
      working among Tropical Diseases Research/World Health Organization(TDR/WHO) in the evaluation
      of drugs and vaccines against Leishmaniasis; besides, PECET belongs to the TDR/WHO Clinical
      Monitors groups, TDR/WHO Data Management and participates in the Initiative for Public Health
      Products Development Doctorate among five Asiatic universities. The Ministry of Social
      Protection is aware of the need of new therapeutic alternatives for Leishmaniasis and has
      requested to PECET to conduct a controlled clinical trial to determinate the efficacy and
      safety of Miltefosine compared with Glucantime for the treatment of Cutaneous Leishmaniasis
      (CL) in Colombia, even though previous, no conclusive trials, conducted in Guatemala and
      Colombia, have demonstrated efficacy this could be an alternative of treatment for this
      country.

      Thermomed is a battery-operated medical device that delivers precisely controlled localized
      current field radio frequency heat to selectively destroy certain diseased tissue. Radio
      frequency energy is directed through the handset to the applicator that is placed in direct
      contact with the lesion. (the applicator contains a thermocouple to continuously monitor and
      control temperature to within 50º Celsius. The thermomed has been used for research on
      treatment for cutaneous leishmaniasis, and recent clinical studies have shown not only
      clinical improvement, but also that therapy elicits an immune response to the disease.
      Through this trial we will try to perform a conclusive clinical evaluation about this drug.

      In summary, with this project to conduct a clinical trial to determine the efficacy and
      safety of Miltefosine or thermotherapy compared with Glucantime for treatment of CL in
      Colombian patients.

      Population CL in is a remerging disease in Colombia affecting civilian and military
      population as well, sharing the same epidemiologic characteristics.

      The selected population will be composed from National Army of Colombia soldiers from CL
      endemic areas (Caquetá, Meta, Guaviare, Putumayo, Córdoba, Antioquia and Chocó).

      Treatment:

      In this phase III, randomized open trial, subjects meeting inclusion criteria of the trial
      will be randomly allocated into two groups according to a randomization list. One group will
      be treated with 150 mg/day of oral miltefosine for 28 days a second group will be treated
      with thermotherapy device used for one session at 50 celsius degrees during 30 seconds and a
      third group will be treated with intramuscular injections of 20 mg/kg/day Glucantime® for 20
      days. A written instruction sheet will be given to each included patient, and the patient
      will be instructed to contact the research team on appearance of symptoms suggesting severe
      side effects (intractable diarrhea and/or vomiting, symptoms of liver, kidney or
      hematopoietic system dysfunction. Until six weeks after the termination of the treatment, any
      patient who received oral miltefosine or was treates with thermotherapy and has active lesion
      will be treated with intramuscular Glucantime® injections (20mg/kg/day for 20 days).

      Study development Schedule of activities Screening (-2 or day 0): Protocol explanation,
      invitation to participate, inform consent signature, parasitological diagnosis (Direct test),
      laboratory tests (Complete hemogram, Ureic Nitrogen (BUN), creatinine, amylase,
      Glutamic-pyruvic transaminase(GTP or ALT), glutamic-oxaloacetic transaminase(GOT or AST)).

      Inclusion (Visit 1): Randomization, sampling of Cultures, physical examination, vital signs
      measure, oral treatment initiation (Miltefosine for 28 days) or Glucantime® intramuscular
      application initiation (for the 20 subsequent days) or thermotherapy ( Local heat), patient's
      clinical record, CRF (Case Report Format) fulfilling, lesions picture taking.

      Visit 2 (Middle of treatment): Laboratory tests (Complete hemogram, BUN, creatinine, amylase,
      GOT, GPT), physical examination, vital signs measure, CRF (Case Report Format) fulfilling,
      Lesions picture taking.

      Visit 3 (End of treatment, +10 days): Laboratory tests (Complete hemogram, BUN, creatinine,
      amylase, GTP, GOT), physical examination, vital signs measure, CRF (Case Report Format)
      fulfilling, lesions picture taking, Evaluation of treatment efficacy.

      Visit 4 (Six weeks after treatment, ± 15 days): Physical examination, Vital signs measure,
      CRF (Case Report Format) fulfilling, lesions picture taking, evaluation of treatment
      efficacy.

      Visit 5 (Three months after treatment, ± 30 days): Physical examination, Vital signs measure,
      CRF (Case Report Format) fulfilling, lesions picture taking, evaluation of treatment
      efficacy.

      Visit 6 (Six months after treatment, ± 40 days): Physical examination, Vital signs measure,
      CRF (Case Report Format) fulfilling, lesions picture taking, evaluation of treatment
      efficacy.

      Procedures:

      Physical examination A complete physical examination will be realized and vital signs will be
      measured.

      Blood samples withdrawn

      Blood samples will be withdrawn from the antecubital vein to perform the following analyses:

        -  Creatinine and Blood Urea Nitrogen.

        -  Alanine transaminase (ALT)

        -  Aspartate transaminase (AST)

        -  Pancreatic amylase.

        -  Complete hemogram.

      Technique for the sampling of cultures The sample for the culture may be obtained by
      suctioning the ulcer active edge in a phosphate-buffered saline solution (PBS) with
      antibiotics (1000 UI of crystalline Penicillin per cc), before it is put in the culture
      medium.

      A tuberculin syringe 0.5 cc of PBS solution with antibiotics is used in the suction
      technique. Previous asepsis of the ulcer with alcohol at 70%, a needle is introduced into the
      dermis and through rotating movements a small amount of tissue is macerated by the needle
      bevel during about a minute, after which it is suctioned into the syringe. The sample is
      deposited in aseptic conditions into a NNN culture medium and incubated at 26°C during 4
      weeks. The strains are identified by species using the monoclonal antibodies.

      Toxicity

      The grade of toxicity will be evaluated according the following parameters:

        -  Systemic: Fever, Headache.

        -  Gastrointestinal: Nausea, vomiting, oral discomfort.

        -  Cardiovascular: cardiac rhythm, hypertension, hypotension.

        -  Musculoskeletal: Arthralgia (joint pain) , myalgia,

      During the treatment and the follow-up visits, the patients will be asked about adverse
      events. Each adverse event will be classified by the physician as serious or non-serious A
      serious adverse event should meet one or more of the following criteria:

        -  Death

        -  Life-threatening (i.e., immediate risk of death)

        -  In-patient hospitalization or prolongation of existing hospitalization

        -  Persistent or significant disability/incapacity The presence of a serious adverse event
           that puts the patient's life at risk and/or requires immediate medical or surgical
           procedure will call for the discontinuation of the treatment and the initiation of the
           pertinent medical management of the patients. The study staff will notify the Adverse
           IEC/IRB of the University of Antioquia of any serious adverse event within 24 hours of
           having knowledge of it.

      A non-serious adverse event will be classified as follows:

      Mild: The patients are aware of their symptoms and/or signs, but those are tolerable. They do
      not require medical intervention or specific treatment.

      Moderate: Patients present troubles that interfere with their daily activities. They require
      medical intervention or specific treatment.

      Severe: The patients are unable to work or to attend their daily activities. They require
      medical intervention or specific treatment.

      The possible relationship between the adverse events and the tested medication will be
      classified by the investigator on the basis of his/her clinical judgment and the following
      definitions:

      Definitely related: Event can be fully explained by the administration of the tested
      medication.

      Probably related: Event is most likely to be explained by the administration of the tested
      medication rather than other medications or by the patient's clinical state.

      Possibly related: Event may be explained by the administration of the tested medication or
      other medications or by the patient's clinical state.

      Not related: Event is most likely to be explained by the patient's clinical state or other
      medications, rather than the tested one.

      Data analysis phase. The healing rate will be calculated according to each group (treatment
      and control) by intention to treat and by protocol. Subgroups will be established depending
      on the clinical response, adverse events and according to Leishmania specie. Besides, the
      characteristics of the lesion (size, localization, type of lesion), demographic
      characteristics and how long the healing takes after the treatment is settled.

      In all cases significance test will be performed to compare both treatments.

      Endpoints Primary Clinical response: Complete re-epithelization of all lesions with
      disappearance of induration (with or without scar). No parasitological evaluation will be
      done on clinically cured lesions determined until 45 days posttreatment.

      Clinical improvement: Reduction of a ≥50% area of induration and ulcer compared with
      immediately previous evaluation.

      Secondary:

      Treatment failure: No change or increase in the size of induration and ulcer. Absence of
      clinical response: Induration and ulcer area ≤50% compared with the immediately previous
      evaluation.

      Final reports At the end of the study the results will be evaluated and discussed and a final
      report presented to Colombian army and Ministry of Social Protection, entities sponsoring the
      project. The relevant results will be published in both, national and international journals,
      and presented in congresses and scientific meetings.

      Ethical aspects This study will be conduced according with the Declaration of Helsinki , the
      Colombian legislation as per the resolution 008430/93 from the Ministry of Health, Canadian
      Council of Animal Care, National Institute for drugs and foods vigilance and control - INVIMA
      (Colombia), International Conference on Harmonisation-Good Clinical Practice (ICH-GCP)
      guidelines, and TDR/WHO guidelines for clinical research.

      Prior to the admission of the patients in the study, the objectives and the methodology will
      be explained and informed consent obtained.

      The study was approved for the Sede de Investigación Universitaria (SIU) bioethics committee
      (CBEIH-SIU) and the Leishmaniasis Committee of the Colombian Military Forces.

      The right to confidentiality of the patients will be maintained in all the phases of the
      study.

      Competing of interests:

      The authors declare that they have no competing of interests.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Clinical Response</measure>
    <time_frame>Until 6 months posttreatment</time_frame>
    <description>Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.
Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Failure</measure>
    <time_frame>Until 3 months posttreatment</time_frame>
    <description>At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence</measure>
    <time_frame>Until 6 months post-treatment</time_frame>
    <description>Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">437</enrollment>
  <condition>Cutaneous Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>Miltefosine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucantime®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucantime® 20 mg /Kg /day for 20 days (intramuscular)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thermotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miltefosine</intervention_name>
    <description>Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.</description>
    <arm_group_label>Miltefosine</arm_group_label>
    <other_name>Impavido®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thermotherapy</intervention_name>
    <description>One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.</description>
    <arm_group_label>Thermotherapy</arm_group_label>
    <other_name>Thermomed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucantime®</intervention_name>
    <description>Glucantime® 20 mg /Kg /day for 20 days (intramuscular)</description>
    <arm_group_label>Glucantime®</arm_group_label>
    <other_name>Glucantime® (meglumine antimoniate)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parasitologically proven cases of CL based on positive smear and/or culture.

          -  Patients belonging to the National Colombian Army.

          -  Otherwise healthy subjects on the basis of medical history, physical examination and
             results of blood test (if seemed necessary by the physician)

          -  Age 18-40 years.

          -  Willing to participate in the study, sign the informed consent , to go to the
             scheduled visits and to the follow-up visits.

          -  Abstain to receive any other treatment for CL during the trial and follow-up periods.

          -  Non purulent lesions.

          -  Mentally sane volunteers.

          -  No Leishmaniasis treatment in the six months prior to the recruitment.

          -  Number of lesions no more than 5

        Exclusion criteria:

          -  None of the lesions must be close to the anal, oral and nasal mucosa, or next to the
             urogenital and anal canal.

          -  Serious systemic illnesses (as judged by the physician)

          -  Patients with mucosal compromise.

          -  Patients with diffuse Leishmaniasis ( defined as 10 or more cutaneous lesions and
             negative Montenegro's test)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan D. Vélez, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Program for Research and Control in Tropical Diseases - PECET (Director)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Program for Research and Control in Tropical Diseases - PECET</name>
      <address>
        <city>Medellín</city>
        <state>Antioquia</state>
        <zip>1226</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <reference>
    <citation>1.World Health Organization. Division of Control of Tropical Diseases. Leishmaniasis control home page. [Consultado: 20 de septiembre de 2006]. Disponible en: www.who.int/health-topics/leishmaniasis.htm</citation>
  </reference>
  <reference>
    <citation>2.Echeverry Gaitan MC, Gaona Narváez J, Gualtero SM. Guia de Atención de Leishmaniasis. Revisión y actualización. 2006.</citation>
  </reference>
  <reference>
    <citation>Bejarano EE, Uribe S, Rojas W, Dario Velez I. Phlebotomine sand flies (Diptera: Psychodidae) associated with the appearance of urban Leishmaniasis in the city of Sincelejo, Colombia. Mem Inst Oswaldo Cruz. 2002 Jul;97(5):645-7.</citation>
    <PMID>12219128</PMID>
  </reference>
  <reference>
    <citation>Bejarano EE, Uribe S, Rojas W, Vélez ID. Presence of Lutzomyia evansi, a vector of American visceral leishmaniasis, in an urban area of the Colombian Caribbean coast. Trans R Soc Trop Med Hyg. 2001 Jan-Feb;95(1):27-8.</citation>
    <PMID>11280058</PMID>
  </reference>
  <reference>
    <citation>Agudelo LA, Uribe J, Sierra D, Ruiz F, Velez ID. Presence of American cutaneous Leishmaniasis vectors surrounding the city of Medellín, Colombia. Mem Inst Oswaldo Cruz. 2002 Jul;97(5):641-2.</citation>
    <PMID>12219126</PMID>
  </reference>
  <reference>
    <citation>Berman J. Report to 1999 Miltefosine PDT of the phase II study. 1999. WHO/TDR.</citation>
  </reference>
  <reference>
    <citation>Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol. 1987 Aug 15;36(16):2633-6.</citation>
    <PMID>3606662</PMID>
  </reference>
  <reference>
    <citation>Ministerio de Proteccion Social, Instituto Nacional de Salud, and SIVIGILA. informe Leishmaniasis semestre 2005. http://www.ins.gov.co/pdf/vcsp/informe_leishmanisis_1sem_2005.pdf. Fecha de acceso: 09/22/06</citation>
  </reference>
  <reference>
    <citation>Leandro C, Campino L. Leishmaniasis: efflux pumps and chemoresistance. Int J Antimicrob Agents. 2003 Sep;22(3):352-7. Review.</citation>
    <PMID>13678842</PMID>
  </reference>
  <reference>
    <citation>Velez ID, Hendrickx E, Robledo SM, del Pilar Agudelo S. [Gender and cutaneous leishmaniasis in Colombia]. Cad Saude Publica. 2001 Jan-Feb;17(1):171-80. Spanish.</citation>
    <PMID>11241940</PMID>
  </reference>
  <reference>
    <citation>Navin TR, Arana BA, Arana FE, de Mérida AM, Castillo AL, Pozuelos JL. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg. 1990 Jan;42(1):43-50.</citation>
    <PMID>2405727</PMID>
  </reference>
  <reference>
    <citation>Velasco-Castrejon O, Walton BC, Rivas-Sanchez B, Garcia MF, Lazaro GJ, Hobart O, Roldan S, Floriani-Verdugo J, Munguia-Saldana A, Berzaluce R. Treatment of cutaneous leishmaniasis with localized current field (radio frequency) in Tabasco, Mexico. Am J Trop Med Hyg. 1997 Sep;57(3):309-12.</citation>
    <PMID>9311641</PMID>
  </reference>
  <reference>
    <citation>Berman JD, Neva FA. Effect of temperature on multiplication of Leishmania amastigotes within human monocyte-derived macrophages in vitro. Am J Trop Med Hyg. 1981 Mar;30(2):318-21.</citation>
    <PMID>7235124</PMID>
  </reference>
  <reference>
    <citation>Sacks DL, Barral A, Neva FA. Thermosensitivity patterns of Old vs. New World cutaneous strains of Leishmania growing within mouse peritoneal macrophages in vitro. Am J Trop Med Hyg. 1983 Mar;32(2):300-4.</citation>
    <PMID>6837841</PMID>
  </reference>
  <reference>
    <citation>Neva FA, Petersen EA, Corsey R, Bogaert H, Martinez D. Observations on local heat treatment for cutaneous leishmaniasis. Am J Trop Med Hyg. 1984 Sep;33(5):800-4.</citation>
    <PMID>6091468</PMID>
  </reference>
  <reference>
    <citation>Wilcocks &amp; Manson-Bahr. Manon's tropical diseases.London: Bailliére Tindall; 1972. p. 119-33.</citation>
  </reference>
  <reference>
    <citation>Herwaldt BL, Arana BA, Navin TR. The natural history of cutaneous leishmaniasis in Guatemala. J Infect Dis. 1992 Mar;165(3):518-27.</citation>
    <PMID>1538157</PMID>
  </reference>
  <reference>
    <citation>Herwaldt BL. Leishmaniasis. Lancet. 1999 Oct 2;354(9185):1191-9. Review.</citation>
    <PMID>10513726</PMID>
  </reference>
  <reference>
    <citation>Remme JH, Blas E, Chitsulo L, Desjeux PM, Engers HD, Kanyok TP, Kengeya Kayondo JF, Kioy DW, Kumaraswami V, Lazdins JK, Nunn PP, Oduola A, Ridley RG, Toure YT, Zicker F, Morel CM. Strategic emphases for tropical diseases research: a TDR perspective. Trends Parasitol. 2002 Oct;18(10):421-6. Review.</citation>
    <PMID>12377584</PMID>
  </reference>
  <reference>
    <citation>Marsden PD. Mucosal leishmaniasis (&quot;espundia&quot; Escomel, 1911). Trans R Soc Trop Med Hyg. 1986;80(6):859-76. Review.</citation>
    <PMID>3037735</PMID>
  </reference>
  <reference>
    <citation>Saravia NG, Weigle K, Segura I, Giannini SH, Pacheco R, Labrada LA, Goncalves A. Recurrent lesions in human Leishmania braziliensis infection--reactivation or reinfection? Lancet. 1990 Aug 18;336(8712):398-402.</citation>
    <PMID>1974943</PMID>
  </reference>
  <reference>
    <citation>Kreutzer RD, Corredor A, Grimaldi G Jr, Grogl M, Rowton ED, Young DG, Morales A, McMahon-Pratt D, Guzman H, Tesh RB. Characterization of Leishmania colombiensis sp. n (Kinetoplastida: Trypanosomatidae), a new parasite infecting humans, animals, and phlebotomine sand flies in Colombia and Panama. Am J Trop Med Hyg. 1991 Jun;44(6):662-75.</citation>
    <PMID>1677544</PMID>
  </reference>
  <reference>
    <citation>Angulo VM, Tarazona Z, Vega A, Vélez Bernal ID, Betancur Martinez J. Leismaniosis Chagas y Malaria. 27-41. 2002. Colombia, Ascofame.</citation>
  </reference>
  <reference>
    <citation>Vélez Bernal ID, Rodriguez Garcia E, Duarte Forero R, López Carvajal L, Castaño Arbeláez M. Enfermedades Tropicales. Guia de manejo de ETV y accidente ofídico. 17-55. 2005. Colombia, PECET</citation>
  </reference>
  <reference>
    <citation>Franke ED, Lucas CM, Tovar AA, Kruger JH, De Rivera MV, Wignall FS. Diffuse cutaneous leishmaniasis acquired in Peru. Am J Trop Med Hyg. 1990 Sep;43(3):260-2.</citation>
    <PMID>2221221</PMID>
  </reference>
  <reference>
    <citation>Hepburn NC, Tidman MJ, Hunter JA. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg. 1994 Nov-Dec;88(6):700-3.</citation>
    <PMID>7886779</PMID>
  </reference>
  <reference>
    <citation>Berman JD. Treatment of New World cutaneous and mucosal leishmaniases. Clin Dermatol. 1996 Sep-Oct;14(5):519-22.</citation>
    <PMID>8889330</PMID>
  </reference>
  <reference>
    <citation>Hendrickx EP, Agudelo SP, Munoz DL, Puerta JA, Velez Bernal ID. Lack of efficacy of mefloquine in the treatment of New World cutaneous leishmaniasis in Colombia. Am J Trop Med Hyg. 1998 Dec;59(6):889-92.</citation>
    <PMID>9886195</PMID>
  </reference>
  <reference>
    <citation>Navin TR, Arana BA, Arana FE, Berman JD, Chajón JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis. 1992 Mar;165(3):528-34.</citation>
    <PMID>1311351</PMID>
  </reference>
  <reference>
    <citation>Franke ED, Wignall FS, Cruz ME, Rosales E, Tovar AA, Lucas CM, Llanos-Cuentas A, Berman JD. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med. 1990 Dec 15;113(12):934-40.</citation>
    <PMID>2173461</PMID>
  </reference>
  <reference>
    <citation>Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis. 2006 May 15;193(10):1375-83. Epub 2006 Apr 7.</citation>
    <PMID>16619185</PMID>
  </reference>
  <reference>
    <citation>Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother. 1992 Aug;36(8):1630-4.</citation>
    <PMID>1329624</PMID>
  </reference>
  <reference>
    <citation>Hepburn NC, Nolan J, Fenn L, Herd RM, Neilson JM, Sutherland GR, Fox KA. Cardiac effects of sodium stibogluconate: myocardial, electrophysiological and biochemical studies. QJM. 1994 Aug;87(8):465-72.</citation>
    <PMID>7922300</PMID>
  </reference>
  <reference>
    <citation>Croft SL, Coombs GH. Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 2003 Nov;19(11):502-8. Review.</citation>
    <PMID>14580961</PMID>
  </reference>
  <reference>
    <citation>Thakur CP, Kumar M, Pandey AK. Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study. Am J Trop Med Hyg. 1991 Oct;45(4):435-41.</citation>
    <PMID>1659239</PMID>
  </reference>
  <reference>
    <citation>Singh S, Sivakumar R. Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother. 2004 Dec;10(6):307-15. Review.</citation>
    <PMID>15614453</PMID>
  </reference>
  <reference>
    <citation>Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis. 1993 Mar;16(3):417-25.</citation>
    <PMID>8384011</PMID>
  </reference>
  <reference>
    <citation>Soto J, Buffet P, Grogl M, Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg. 1994 Jan;50(1):107-11.</citation>
    <PMID>8304565</PMID>
  </reference>
  <reference>
    <citation>Amato VS, de Paula JG, Imamura R, Amato Neto V, Duarte MI, Boulos MI, Boulos M, Nicodemo AC, de Mendonca JS. [Treatment of american cutaneous leishmaniasis, with lesions in the mucosa, using pentamidine isethionate]. Rev Soc Bras Med Trop. 1996 Sep-Oct;29(5):477-81. Portuguese.</citation>
    <PMID>8966312</PMID>
  </reference>
  <reference>
    <citation>Correia D, Macêdo VO, Carvalho EM, Barral A, Magalhães AV, de Abreu MV, Orge ML, Marsden P. [Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis]. Rev Soc Bras Med Trop. 1996 Sep-Oct;29(5):447-53. Portuguese.</citation>
    <PMID>8966308</PMID>
  </reference>
  <reference>
    <citation>Amato V, Amato J, Nicodemo A, Uip D, Amato-Neto V, Duarte M. [Treatment of mucocutaneous leishmaniasis with pentamidine isothionate]. Ann Dermatol Venereol. 1998 Aug;125(8):492-5. French.</citation>
    <PMID>9747313</PMID>
  </reference>
  <reference>
    <citation>Robledo SM, Puerta JA, Muñoz DL, Guardo M, Vélez ID. [Efficacy and tolerance of pentamidine for treatment of cutaneous leishmaniasis caused by por L. (V) panamensis in Colombia]. Biomedica. 2006 Oct;26 Suppl 1:188-93. Spanish.</citation>
    <PMID>17361854</PMID>
  </reference>
  <reference>
    <citation>de Paula CD, Sampaio JH, Cardoso DR, Sampaio RN. [A comparative study between the efficacy of pentamidine isothionate given in three doses for one week and N-methil-glucamine in a dose of 20mgSbV/day for 20 days to treat cutaneous leishmaniasis]. Rev Soc Bras Med Trop. 2003 May-Jun;36(3):365-71. Epub 2003 Jul 31. Portuguese.</citation>
    <PMID>12908038</PMID>
  </reference>
  <reference>
    <citation>Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, Luz-Cjuno M, Echevarria J, Miranda-Verastegui C, Colina O, Berman JD. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis. Am J Trop Med Hyg. 2005 Feb;72(2):133-7.</citation>
    <PMID>15741547</PMID>
  </reference>
  <reference>
    <citation>Lieber-Mbomeyo A, Lipsker D, Miléa M, Heid E. [Rhabdomyolysis induced by pentamidine (Pentacarinat) during treatment of cutaneous leishmaniasis: 2 cases]. Ann Dermatol Venereol. 2002 Jan;129(1 Pt 1):50-2. French.</citation>
    <PMID>11937930</PMID>
  </reference>
  <reference>
    <citation>Lightburn E, Morand JJ, Meynard JB, Kraemer P, Chaudier B, Pages F, Garnotel E, Patte JH, Banzet S, Dampierre H, Lepage J, Morillon M, Boutin JP, Hovette P, Chouc C. [Management of American cutaneous leishmaniasis. Outcome apropos of 326 cases treated with high-dose pentamidine isethionate]. Med Trop (Mars). 2003;63(1):35-44. French.</citation>
    <PMID>12891748</PMID>
  </reference>
  <reference>
    <citation>Delobel P, Pradinaud R. Rhabdomyolysis associated with pentamidine isethionate therapy for American cutaneous leishmaniasis. J Antimicrob Chemother. 2003 May;51(5):1319-20. Epub 2003 Mar 28.</citation>
    <PMID>12668576</PMID>
  </reference>
  <reference>
    <citation>Hauben M, Reich L. A case report of rhabdomyolysis with pentamidine that prompted a retrospective evaluation of a pharmacovigilance tool under investigation. Br J Clin Pharmacol. 2004 Dec;58(6):675-6.</citation>
    <PMID>15563366</PMID>
  </reference>
  <reference>
    <citation>Invetigator's Brochure Miltefosine. D-18506. 27-10-1999. Frankfurt, Alemania, ASTA Medica</citation>
  </reference>
  <reference>
    <citation>Croft SL, Snowdon D, Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother. 1996 Dec;38(6):1041-7.</citation>
    <PMID>9023651</PMID>
  </reference>
  <reference>
    <citation>Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, Hilgard P, Murray HW. Trial of oral miltefosine for visceral leishmaniasis. Lancet. 1998 Dec 5;352(9143):1821-3.</citation>
    <PMID>9851383</PMID>
  </reference>
  <reference>
    <citation>Verweij J, Planting A, van der Burg M, Stoter G. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours. J Cancer Res Clin Oncol. 1992;118(8):606-8.</citation>
    <PMID>1325463</PMID>
  </reference>
  <reference>
    <citation>Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis. 2004 May 1;38(9):1266-72. Epub 2004 Apr 9.</citation>
    <PMID>15127339</PMID>
  </reference>
  <reference>
    <citation>Alvaro Ruíz Morales, Luis Enrique Morrillo Zárate. Epidemiología clínica. Bogotá, Editorial Médica Panamericana</citation>
  </reference>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2007</study_first_submitted>
  <study_first_submitted_qc>May 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2007</study_first_posted>
  <results_first_submitted>June 14, 2010</results_first_submitted>
  <results_first_submitted_qc>June 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 14, 2010</results_first_posted>
  <last_update_submitted>July 15, 2010</last_update_submitted>
  <last_update_submitted_qc>July 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Universidad de Antioquia</name_title>
    <organization>Universidad de Antioquia</organization>
  </responsible_party>
  <keyword>Miltefosine</keyword>
  <keyword>Leishmaniasis</keyword>
  <keyword>Glucantime</keyword>
  <keyword>Thermotherapy</keyword>
  <keyword>Colombia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miltefosine</mesh_term>
    <mesh_term>Meglumine antimoniate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was carried out between June 2006 and April 2008. The subjects of the study were adult males serving in the Colombian Army. The study was carried out in five military health establishments located in central, northeast and southern Colombia.</recruitment_details>
      <pre_assignment_details>Screening was performed to 486 volunteers, of whom 49 were excluded for several reasons, as follows: Failure to meet inclusion criteria (n=12), unwillingness to participate (n=14) and completion of military service within 6 months (n=23)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Miltefosine</title>
          <description>Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.</description>
        </group>
        <group group_id="P2">
          <title>Glucantime®</title>
          <description>Glucantime® 20 mg /Kg /day for 20 days (intramuscular)</description>
        </group>
        <group group_id="P3">
          <title>Thermotherapy</title>
          <description>One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="143"/>
                <participants group_id="P3" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="121"/>
                <participants group_id="P3" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Miltefosine</title>
          <description>Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.</description>
        </group>
        <group group_id="B2">
          <title>Glucantime®</title>
          <description>Glucantime® 20 mg /Kg /day for 20 days (intramuscular)</description>
        </group>
        <group group_id="B3">
          <title>Thermotherapy</title>
          <description>One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="145"/>
            <count group_id="B2" value="143"/>
            <count group_id="B3" value="149"/>
            <count group_id="B4" value="437"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" lower_limit="19" upper_limit="37"/>
                    <measurement group_id="B2" value="23" lower_limit="19" upper_limit="38"/>
                    <measurement group_id="B3" value="23" lower_limit="19" upper_limit="39"/>
                    <measurement group_id="B4" value="23" lower_limit="19" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Clinical Response</title>
        <description>Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.
Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment.</description>
        <time_frame>Until 6 months posttreatment</time_frame>
        <population>The efficacy of the treatments was calculated by intention to treat and by protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Miltefosine</title>
            <description>Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.</description>
          </group>
          <group group_id="O2">
            <title>Glucantime®</title>
            <description>Glucantime® 20 mg /Kg /day for 20 days (intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Thermotherapy</title>
            <description>One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Clinical Response</title>
          <description>Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.
Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment.</description>
          <population>The efficacy of the treatments was calculated by intention to treat and by protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence</title>
        <description>Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up.</description>
        <time_frame>Until 6 months post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Miltefosine</title>
            <description>Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.</description>
          </group>
          <group group_id="O2">
            <title>Glucantime®</title>
            <description>Glucantime® 20 mg /Kg /day for 20 days (intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Thermotherapy</title>
            <description>One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence</title>
          <description>Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Failure</title>
        <description>At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment</description>
        <time_frame>Until 3 months posttreatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Miltefosine</title>
            <description>Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.</description>
          </group>
          <group group_id="O2">
            <title>Glucantime®</title>
            <description>Glucantime® 20 mg /Kg /day for 20 days (intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Thermotherapy</title>
            <description>One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.</description>
          </group>
        </group_list>
        <measure>
          <title>Failure</title>
          <description>At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During treatment and 6 months after treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Miltefosine</title>
          <description>Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.</description>
        </group>
        <group group_id="E2">
          <title>Glucantime®</title>
          <description>Glucantime® 20 mg /Kg /day for 20 days (intramuscular)</description>
        </group>
        <group group_id="E3">
          <title>Thermotherapy</title>
          <description>One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Death in combat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="130"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Erythrocytes (Middle of treatment)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="100"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Leukocytes (Middle of treatment)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Haemoglobin (End of treatment)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Erythrocytes (End of treatment)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting (Middle of treatment)</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="130"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Nausea (Middle of treatment)</sub_title>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="130"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Anorexia (Middle of treatment)</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="130"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Vomiting (End of treatment)</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="129"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="131"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Nausea (End of treatment )</sub_title>
                <counts group_id="E1" events="59" subjects_affected="59" subjects_at_risk="129"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="131"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Anorexia (End of treatment )</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="129"/>
                <counts group_id="E2" events="45" subjects_affected="45" subjects_at_risk="131"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Diarrhea (End of treatment)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Abdominal Pain (End of treatment)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="fever">Fever (Middle of treatment)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="130"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="119"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Cephalea (Middle of treatment)</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="130"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="119"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Fever (End of treatment)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="131"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Cephalea (End of treatment)</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="129"/>
                <counts group_id="E2" events="52" subjects_affected="52" subjects_at_risk="131"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ALT (Middle of treatment)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Amylase (Middle of treatment)</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="115"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="111"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>AST (End of treatment)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>ALT (End of treatment)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="112"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Amylase (End of treatment )</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="109"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia (Middle of treatment)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="130"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="119"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Arthralgia (Middle of treatment)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="130"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="119"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Myalgia (End of treatment)</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="129"/>
                <counts group_id="E2" events="67" subjects_affected="67" subjects_at_risk="131"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Arthralgia (End of treatment)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="129"/>
                <counts group_id="E2" events="65" subjects_affected="65" subjects_at_risk="131"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>BUN (Middle of treatment)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>BUN (End of treatment)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Iván Darío Vélez Bernal</name_or_title>
      <organization>Universidad de Antioquia - Colombia</organization>
      <phone>574 + 219 6501 - 02</phone>
      <email>idvelez@pecet-colombia.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

